Hyrimoz

Adalimumab, the active ingredient in Hyrimoz, is a tumor necrosis factor (TNF) inhibitor presented as a sterile subcutaneous injection for systemic use. It binds TNF‑α, reducing inflammatory signaling, and is prescribed for adult patients with chronic autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

GNH USA supplies Hyrimoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for biologic therapies.

Hyrimoz is a biologic disease‑modifying antirheumatic drug that targets the TNF‑α pathway in inflammatory autoimmune diseases. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriatic arthritis: alleviates joint pain and skin lesions. - Ankylosing spondylitis: improves spinal mobility and reduces pain. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing. - Plaque psoriasis: decreases skin scaling and erythema.

Adalimumab may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory infections: sinusitis, nasopharyngitis, or bronchitis. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Rash: mild skin eruptions. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Serious infections: tuberculosis, bacterial sepsis, or opportunistic infections. - Malignancies: lymphoma or other cancers. - Demyelinating disease: new or worsening neurologic symptoms. - Heart failure: worsening of pre‑existing cardiac conditions. - Lupus‑like syndrome: development of auto‑immune symptoms. - Cytopenias: low blood cell counts such as neutropenia or anemia.

Before initiating therapy with Hyrimoz, clinicians should evaluate several safety considerations. - Screen for active infections: test for tuberculosis, hepatitis B/C, and HIV. - Assess vaccination status: avoid live vaccines during treatment. - Monitor for malignancy: conduct regular cancer screenings as indicated. - Evaluate cardiac function: use caution in patients with heart failure. - Review laboratory values: monitor complete blood count and liver enzymes periodically. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - Concurrent biologic immunosuppressants: increase risk of serious infections. - Severe active infection: therapy should be withheld.

Moderate Interactions (Monitor Closely): - Methotrexate: may enhance immunosuppression; monitor blood counts. - Azathioprine or 6‑mercaptopurine: increased infection risk. - Cyclosporine: potential additive immunosuppressive effect. - Non‑live vaccines: may have reduced efficacy; assess response. - NSAIDs: monitor for gastrointestinal bleeding when combined with steroids.